2seventy bio (NASDAQ:TSVT) Given Market Perform Rating at Leerink Partners

Leerink Partners restated their market perform rating on shares of 2seventy bio (NASDAQ:TSVT) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $5.00 price objective on the stock, down from their previous price objective of $9.00.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of 2seventy bio in a research report on Friday, March 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, 2seventy bio presently has a consensus rating of “Hold” and a consensus price target of $6.83.

2seventy bio Stock Up 76.8 %

Shares of TSVT stock opened at $4.95 on Tuesday. The stock has a market capitalization of $255.36 million, a PE ratio of -2.66 and a beta of 1.73. 2seventy bio has a 52-week low of $2.29 and a 52-week high of $5.99. The stock’s 50-day moving average price is $2.60 and its 200 day moving average price is $3.68.

Institutional Investors Weigh In On 2seventy bio

A number of institutional investors have recently added to or reduced their stakes in TSVT. GSA Capital Partners LLP purchased a new stake in 2seventy bio in the 3rd quarter valued at approximately $64,000. Intech Investment Management LLC purchased a new stake in 2seventy bio in the 3rd quarter valued at approximately $69,000. FMR LLC boosted its stake in shares of 2seventy bio by 22.0% during the 3rd quarter. FMR LLC now owns 148,545 shares of the company’s stock worth $701,000 after acquiring an additional 26,738 shares in the last quarter. BBR Partners LLC boosted its stake in shares of 2seventy bio by 620.0% during the 3rd quarter. BBR Partners LLC now owns 180,000 shares of the company’s stock worth $850,000 after acquiring an additional 155,000 shares in the last quarter. Finally, PDT Partners LLC purchased a new stake in shares of 2seventy bio during the 3rd quarter worth approximately $244,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.